Gallop Oncology's LYT-200 Shows Strong Efficacy with 13.2 Months Survival in AML
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Efficacy Breakthrough: LYT-200 demonstrated an initial median overall survival of 13.2 months in heavily pretreated patients when combined with standard care, significantly exceeding the expected survival of less than 2.5 months in acute myeloid leukemia (AML), indicating its potential in treatment.
- Favorable Safety Profile: In a trial involving 101 participants, LYT-200 showed no treatment-related serious adverse events, highlighting its good tolerability and supporting further development in AML patients.
- Broad Applicability: Responses were observed in patients with various high-risk mutations, suggesting LYT-200's potential applicability in AML and beyond, enhancing its market prospects.
- Clinical Trial Progress: Gallop Oncology plans to release final survival data in the first half of 2026 and engage with regulatory authorities regarding the registration pathway for LYT-200, demonstrating the company's confidence in the drug's future development.
PRTC.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PRTC
About PRTC
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?